Apoptosis of bladder cancer by sodium butyrate and cisplatin

Journal of Infection and Chemotherapy

Volumn 18, Issue 3, 2012, Pages 288-295

  Maruyama, Takuo ^a   Yamamoto, Shingo ^a   Qiu, Jun ^a   Ueda, Yasuo ^a   Suzuki, Toru ^a   Nojima, Michio ^a   Shima, Hiroki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bladder cancer; Cisplatin; Sodium butyrate

Indexed keywords

BUTYRIC ACID; CASPASE; CASPASE 2; CASPASE 7; CISPLATIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROCASPASE 2; PROCASPASE 7; PROTEIN P21; PROTEIN P27; PROTEIN PRECURSOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; PROTEIN EXPRESSION;

EID: 84863308529     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0322-2     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001;18:109-14.
3. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, et al. Butyrate sensitizes human colon cancer cells to TRAILmediated apoptosis. Surgery (St. Louis). 2001;130:265-72.
4. Chopin V, Toillon RA, Jouy N, Le Bourhis X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol. 2002;135:79-86.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
6. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylases inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13:477-83.
7. Vigushin DM, Coombes RC. Histone deacetylases inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1-13.
8. Gray SG, Ekström TJ. The human histone deacetylase family. Exp Cell Res. 2001;262:75-83.
9. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423-30.
10. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther. 2002;1:1181-90.
11. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog. 2003;38:59-69.
12. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004;23:21-9.
13. Wang ZM, Hu J, Zhou D, Xu ZY, Panasci LC, Chen ZP. Trichostatin A inhibits proliferation and induces expression of P21WAF and p27 in human brain tumor cell lines. Ai Zheng. 2002;21:1100-5.
14. Chen Z, Clark S, Birkeland M, Sung CM, Lago A, Liu R, et al. Induction and super-induction of growth arrest and DNA damage 45(GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 2002;188:127-40.
15. Kim YB, Ki SW, Yoshida M, Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo). 2000;53:1191-200.
16. Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol. 2006;13:581-6.
17. Gould JJ, Kenney PA, Rieger-Christ KM, Silva Neto B, Wszolek MF, LaVoie A, et al. Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol. 2010;183:2395-402.
18. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol. 2008;15:435-41.
19. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int J Oncol. 2000;17:1213-8.
20. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci. 2001;58: 728-36.
21. Qiu J, Yamamoto S, Maruyama T, Kondoh N, Nojima M, Shima H. Growth suppression of prostate cancer cells by sodium butyrate in vitro. Acta Med Hyogo. 2007;32:77-85.
22. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature (Lond). 1993; 366:701-4.
23. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cipl is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993;75:805-16.
24. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.
25. Lacombe L, Orlow I, Silver D, Gerald WL, Fair WR, Reuter VE, et al. Analysis of p21Waf1/CIP1 in primary bladder tumors. Oncol Res. 1996;8:409-14.
26. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014-9.
27. Hashimoto-Tamaoki T. Control of the cell cycle: cloning and functional analyses of the tumor suppressor genes. Acta Med Hyogo. 2002;27:167-81.
28. Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, et al. Demethylating agent 5-aza-20-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology. 2008;71:1220-5.
29. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997;57:1758-68.
30. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity. 1999;10:629-39.
31. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE. Apoptosis and chemotherapy for bladder cancer. J Urol. 2005;173:683-90.
32. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol. 2009;10:348-55.
33. Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer. 2000;88:986-91.
34. Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. A tumor suppressor function for caspase-2. Proc Natl Acad Sci USA. 2009;106:5336-41.
35. Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R. Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis. 2007;12:1901-9.
36. Lin J, Zhang Z, Yang J, Zeng S, Liu BF, Luo Q. Real-time detection of caspase-2 activation in a single living HeLa cell during cisplatininduced apoptosis. J Biomed Opt. 2006;11:024011.